Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...swire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Na...from the Company,s Bepreve(TM) (bepotastine besila...ies. These results were presented in poster sessi...lege of Allergy, Asthma & Immunology (ACAAI) i... titled, "Treatment of Ocular Itching with Bepotas...
(Date:11/9/2009)... 9 Decision Resources, one of the ...armaceutical and healthcare issues, finds that, in...ER2) targeting therapies -- which include Roche/Ch...,s Tykerb/Tyverb -- were the highest-selling drug ... of Herceptin and Tykerb/Tyverb and the expected l...
(Date:11/9/2009)... Shire plc (LSE: SHP...ceutical company, today announced the availability...Tablets in pharmacies across the United States for...Disorder ( ADHD ) in children and adolescents ag...guanfacine, is the first and only nonscheduled alp...
Breaking Medicine Technology:ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 4Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 5Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 6Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 7Ex White House Drug Spokesman Urges Double Drug Treatment 3B Bob Weiner and Policy Analyst Zoe Pagonis Highlight Drug Wars Wrong Focus 52806 1Ex White House Drug Spokesman Urges Double Drug Treatment 3B Bob Weiner and Policy Analyst Zoe Pagonis Highlight Drug Wars Wrong Focus 52806 2Iowa Committee Produces Principles for National Efforts to Reform Health Care 52803 1Iowa Committee Produces Principles for National Efforts to Reform Health Care 52803 2Iowa Committee Produces Principles for National Efforts to Reform Health Care 52803 3Mayor Menino Joins The Salvation Army to Celebrate the Groundbreaking of the Kroc Community Center 52800 1Mayor Menino Joins The Salvation Army to Celebrate the Groundbreaking of the Kroc Community Center 52800 2Mayor Menino Joins The Salvation Army to Celebrate the Groundbreaking of the Kroc Community Center 52800 3
...rauma or,noise-induced hearing loss. By any name, ...nent hearing loss. Up to 28 million Americans,have...c trauma is a,significant contributor, reports the...., Acoustic trauma is a product of modern life. O... but recreational noise -- such as loud music --,i...
...nificantly Improve Overall Survival in .... and EMERYVILLE, Calif., Nov. 19 ,Bayer HealthCar...Nasdaq:,ONXX) today announced that the U.S. Food a...mental New Drug Application for Nexavar(R) (sorafe...resectable hepatocellular,carcinoma (HCC), or live...
Other Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:11/9/2009)...n,t answer question of why this is so, however , ...ter a lumpectomy, women with very dense breasts ha...ted breast, a new study shows. , Breast density... developing breast cancer, and experts have suspec... with an increased risk of cancer recurrence at th...
(Date:11/9/2009)...TSFIELD, Maine, Nov. 9 At a time w...aine are increasingly concerned about finding affo...ve Medicare option for 2010. ,, The Today,s Opt...edicare Advantage plan provides a cost-effective a...or a Medicare Supplement plan. People with Medica...
(Date:11/9/2009)...urologists will use funds to move lab findings int...hat involves pain from nerve damage ,, ANN ARB...chers from the University of Michigan Department o...develop a novel therapy for neuropathic pain, a di...ience pain because of damage to nerve without obvi...
(Date:11/9/2009)...sburg, Va. In the construction industry, respirat...reased risk of cancer, is a major public health co...culty member in Virginia Tech,s School of Construc...ols are highly effective in reducing the dust that...sage of the available technology remains very low....
(Date:11/9/2009)...gton, DC) Physician bias might be the reason why A... transplants at the same rate as similar patients ...tor of kidney and pancreas transplantation at Geor... of surgery at Georgetown University Medical Cente...ovember issue of the American Journal of Transpla...
Breaking Medicine News(10 mins):Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:Physician bias might keep life-saving transplants from black and Hispanic patients 2
...-label, uses, report suggests , , MONDAY, ...better than the bare-metal kind for treating compl...e are two messages I would take away from the stud... of the American College of Cardiology. "The firs...
...er Nutrition,( http://www.betternutrition.com ), t... magazine, announced today the winners of their "B...n the natural products industry, this,program reco...nce Facial Cleanser, Avalon Organics Co Enzyme Q1...
...e Cuts to Home Oxygen Benefit Proposed;,$1.5 Billi...ct in Less than,One Year, WASHINGTON, Feb. 4 The...coalition of the nation,s 11 leading home,oxygen t...dministration,s proposed budget. According to the,...
...08 Deborah E. Wiley, Chairman of The Wiley Founda..., Inc., announced today that the seventh annual Wi...o Dr. Richard P. Lifton of the Yale University Sch...ty School of Medicine, and Investigator of the How...
...sident,Medicine & Science, American Diabetes Assoc... statement in response to the Bush Administration,...y, which would continue to,under-fund diabetes res...udget proposal, funding for the National,Institute...
...rly conjoined twins,Yurelia and Fiorella Rocha-Ari... Stanford and are now home in Costa Rica. Accordin...ildren,s last Wednesday (30) and went,to Southern ...a, where an entire nation will celebrate their,suc...
Other Medicine News:Health News:Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases 2Health News:Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases 3Health News:Better Nutrition Announces 'Best Of Beauty Awards' Winners Showcasing the Best Natural Beauty Products of 2008 2Health News:Home Oxygen Care Leaders Say President's Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts 2Health News:Home Oxygen Care Leaders Say President's Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts 3Health News:7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton 2Health News:7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton 3Health News:Statement of the American Diabetes Association on the Administration's Proposal to Undermine Funds for Research, Prevention and Treatment in FY09 2Health News:Formerly Conjoined Twins Leave Packard Children's Hospital; Heading Home to Costa Rica 2
TigerStick™
...offers the Flowmaster. It is a new portable digita...studies, where ease of use, simplicity and cost ef...eless uroflowmeter which makes it now very easy to...wmaster anywhere you want and data will be send wi...
UroPass® II Open Tip Ureteral Stents
Classic Open Tip Ureteral Stents
Medicine Products: